Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
Conditions: Hepatocellular Carcinoma; TACE; Anlotinib Interventions: Drug: Anlotinib Hydrochloride; Procedure: TACE Sponsors: First Affiliated Hospital Xi'an Jiaotong University; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research